Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Quebec. For further information about Targanta, visit the company's website at www.targanta.com.

Contact Information

222 Third Street
Suite 2300
Cambridge, MA 02142-1122

tel: 617-577-9020
fax: 617-577-9021


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $180.3M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.